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Diabetic neuropathy (DN) is a widespread disabling disorder comprising peripheral nerves’ damage. DN develops on a background
of hyperglycemia and an entangled metabolic imbalance, mainly oxidative stress. The majority of related pathways like polyol,
advanced glycation end products, poly-ADP-ribose polymerase, hexosamine, and protein kinase c all originated from initial
oxidative stress. To date, no absolute cure for DN has been defined; although some drugs are conventionally used, much more
can be found if all pathophysiological links with oxidative stress would be taken into account. In this paper, although current
therapies for DN have been reviewed, we have mainly focused on the links between DN and oxidative stress and therapies on
the horizon, such as inhibitors of protein kinase C, aldose reductase, and advanced glycation. With reference to oxidative stress
and the related pathways, the following new drugs are under study such as taurine, acetyl-L-carnitine, alpha lipoic acid, protein
kinase C inhibitor (ruboxistaurin), aldose reductase inhibitors (fidarestat, epalrestat, ranirestat), advanced glycation end product
inhibitors (benfotiamine, aspirin, aminoguanidine), the hexosamine pathway inhibitor (benfotiamine), inhibitor of poly ADP-
ribose polymerase (nicotinamide), and angiotensin-converting enzyme inhibitor (trandolapril).The development of modern drugs
to treat DN is a real challenge and needs intensive long-term comparative trials.
1. Introduction
A conduction problem arising in peripheral nerves is called
peripheral neuropathy. Depending on the cause, the damage
may appear in the axons or the myelin sheaths. The involved
neurons may be afferent (sensory), efferent (motor), or
both. The size of affected axons is an important issue, since
sometimes only the small C unmyelinated and the A-delta
fibers are affected. If these are damaged, symptoms move
forward to pain sensors in the skin and autonomic neurons.
Damage to large sensory fibers, which are the A-alpha and A-
beta fibers, causes deficits in the proprioception and vibration
sensation that results in muscle-stretch reflexes [1].
Diabetic neuropathy (DN), a microvascular complica-
tion of diabetes, comprises disorders of peripheral nerve
in people with diabetes when other causes are ruled out.
Diabetic peripheral neuropathy (DPN) is associated with
considerable mortality, morbidity, and diminished quality of
life [2]. The prevalence of neuropathy in diabetic patients
is about 30%, whereas up to 50% of patients will certainly
develop neuropathy during their disease [3]. In fact, against
estimated universal prevalence of diabetes of 472 million by
2030, DPN is likely to affect 236 million persons worldwide
causing lots of costs [4]. DPN can be broadly divided into
generalized polyneuropathies and focal/multifocal varieties
[5, 6]. The generalized form can be further classified into
typical and atypical in terms of difference in onset, course,
associations, clinical manifestations, and pathophysiology.
The typical DPN is a chronic, symmetrical length-dependent
sensorimotor polyneuropathy (DSPN) and the most com-
mon presentation of the peripheral nervous system damage
by diabetes [7]. Therefore, considering the widespread of
DN, it is vital to investigate details of its pathophysiology
and therapeutic strategies. DN develops on a background of
hyperglycemia and associated metabolic imbalances mainly
oxidative stress. Hyperglycemia-induced overproduction of
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free radicals has been recognized as the source of further
complications. Studies in the recent years have identified
major pathways that are linked to DN, such as stimulated
polyol, advanced formation of glycation end products, and
other cascades of stress responses [8]. Since oxidative stress
leads to such a major influence in the development of DN,
in this paper we have highlighted the evidence linking DN,
oxidative stress, and its consequences.
Despite efforts to make an early diagnosis and to stop the
progression of DN, currently very few drugs are available to
cure this disease and the others only provide symptomatic
relief. Meanwhile, current goal of treatment of DN is to
increase the functionality and quality of life and to diminish
pain. In the present review, therapies on the horizon based on
oxidative stress have been criticized.
2. Methods
Databases of PubMed, Google Scholar, Web of Science,
Embase, Scopus, and DARE were searched up to 30 Novem-
ber 2012, for all relevant studies with DN. The search terms
were diabetic neuropathy, oxidative stress, mechanisms, and
current and new treatmentswithout limiting search elements.
All of relevant human (Table 1) and animal (Table 2) studies
were included.
3. Clinical Features of DN
The most common form of DN is DSPN that accounts for
a large proportion of all peripheral nerve manifestations
attributed to diabetes, although, some physicians use the
terms DSPN and DN interchangeably. Poor control of blood
glucose is an important risk factor for the development of
DN starting in the toes and gradually progressing proximally.
Once it is diagnosed in the lower limbs, it may develop to
the upper limbs with sensory loss [4]. For example, a patient
with painful sensory neuropathy due to diabetes might first
complain of burning or itchy sensations or even pain in the
feet that is called paresthesias. The symptoms distribute on
a so-called “glove and stocking” manner, as it starts from
the longest axons. The unmyelinated nerve endings in the
epidermis are degenerated first [2]. Neuropathic pain is the
most disabling symptom observed in around one-third of
patients with DN and about 20% of all diabetic patients.
Painful DN deleteriously influences quality of life, sleep,
mood, and the ability to work [4].
4. Pathogenesis of DN:
Interaction of Oxidative Stress with
Other Physiological Pathways
Although development of DN is multifactorial and the exact
pathogenic mechanism is yet to be understood, a number
of theories can be described. The current belief is that
hyperglycemia, activation of polyol, advanced glycation end
products (AGEs), hexosamine, diacylglycerol/protein kinase
C (PKC), oxidative stress, nitric oxide, and inflammation all
play key roles in DN. Based on evidence, oxidative stress
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Figure 1: Interaction of oxidative stress with other physiological
pathways in DN.
is involved in all the above pathways (see Figure 1). These
mechanisms are described one by one in the next sections of
this paper, and then a conclusion is made.
4.1. Hyperglycemia. Excess intracellular glucose is processed
by increased flux via one or more glucose metabolism path-
ways, and thus prolonged hyperglycemia results in progress
of chronic complications of diabetes including DN.
4.2. Role of Polyol. Hyperglycemia results in elevated intra-
cellular glucose in nerves, leading to saturation of the normal
glycolytic pathway. Extra glucose lightens up the polyol path-
way and that produces sorbitol and subsequently fructose
by aldose reductase and sorbitol dehydrogenase, respectively.
Increased polyol flux causes intracellular hyperosmolarity
by an accumulation of impermeable sorbitol and compen-
satory efflux of other osmolytes such as myoinositol, taurine,
and adenosine. In turn, shortage of myoinositol results in
exhaustion of phosphatidylinositol and withdraws creation
of adenosine triphosphate (ATP). All these processes result
in a reduced activity of Na+/K+-ATPase and PKC, impaired
axonal transport and structural breakdown of nerves, and
finally presents itself as abnormal action potential. Aldose
reductase-mediated reduction of glucose to sorbitol is asso-
ciated with consumption of NADPH, and since NADPH is
required for regeneration of reduced glutathione (GSH), this
directly contributes to oxidative stress. In addition, forma-
tion of fructose from sorbitol promotes glycation, depletes
NADPH, and increases AGEs which all result in major redox
imbalance (see Figure 2) [9, 10].
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Table 2: New therapeutic approaches for DN. DRG: dorsal root ganglion neuron.
Endpoint Study populations Compound Study
Improvement of peripheral nerve
function Diabetic rats Salvianolic acid A Yu et al. [79]
Improvement of DN Animal model of T2D High-fat diet with menhaden oil Coppey et al. [80]
Improvement of DN Patients with T2D and neuropathy Tai Chi exercise Ahn and Song [81]
Improvement of DN T2DM patients Beraprost sodium Shin et al. [82]
Improvement of DN STZ-diabetic rats Anandamide Schreiber et al. [83]
Improvement of peripheral nerve
function Mouse model of DPN Thymosin 𝛽4 Wang et al. [84]
Improvement of chronic pain,
including PDN Rat model of STZ-induced PDN Gastrodin Sun et al. [85]
Prevention of progression of DN
Patients enrolled in the aldose
reductase inhibitor-diabetes
complications
Epalrestat Hotta et al. [86]
Improvement of DN STZ-diabetic rats Gliclazide with curcumin Attia et al. [87]
Improvement of DN STZ-diabetic rats Bone marrow-derivedmononuclear cells Naruse et al. [88]
Neuroprotection effect In vitro model of high glucose-treatedDRG neurons in culture Galanin Xu et al. [89]
Improvement of DN — Baicalein Yorek [90]
Improvement of neuropathic pain Animal models of neuropathic pain Brazilian armed spider venomtoxin Tx3-3 Dalmolin et al., [91]
Neuroprotection effect
Improvement of DN STZ-diabetic rats
Magnesium-25 carrying
porphyrin-fullerene
nanoparticles
Hosseini et al. [92, 93]
Maintaining health in diabetes STZ-diabetic rats Phosphodiesterase inhibitors Milani et al. [94]
Improve transplant outcome and
graft function in diabetes Isolated rat pancreatic islets IMOD Larijani et al. [95]
Improve islet transplantation in
diabetes Isolated rat pancreatic islets
Cerium and yttrium oxide
nanoparticles
Hosseini and Abdollahi
[96, 97]
4.3. Role of AdvancedGlycation End Products (AGEs). Hyper-
glycemia accelerates generation of AGEs via attachment of
reactive carbohydrate groups to proteins, nucleic acids, or
lipids. These groups tend to damage the biological task of
proteins, which as a result affects cellular function. Extracel-
lular AGEs also bind to the receptor of AGE (RAGE) and
initiate inflammatory flows, activate NADPH oxidases, and
generate oxidative stress. Long-term inflammatory responses
upregulate RAGE and stimulate nuclear factor kappa B
(NF𝜅B). Collectively, the biochemical damage induced by
AGEs results in diminished neurotrophic support, impaired
nerve blood flow, disrupted neuronal integrity, and impaired
repair mechanisms (Figure 2) [3, 10].
4.4. Role of Hexosamine. The hexosamine, an additional
factor, is implicated in the pathology of diabetes-induced
oxidative stress and its complications. Fructose-6 phos-
phate, a metabolic intermediate of glycolysis, is shifted
from the glycolytic pathway to the hexosamine way where
fructose-6 phosphate is converted to uridine diphosphate-
N-acetylglucosamine (UDPGlcNAc).Then, the UDPGlcNAc
attaches to the serine and threonine residues of transcrip-
tion factors. Hyperglycemic conditions create additional flux
through hexosamine pathway that ultimately result in an
increased activation of Sp1, a transcription factor impli-
cated in diabetic complications. Activation of Sp1 leads to
overexpression of transforming growth factor-𝛽1 (TGF-𝛽1)
and plasminogen activator inhibitor-1 (PAI-1). The PAI-
1 is upregulated by both hexosamine and PKC pathways.
Collectively, activation of hexosamine pathway is implicated
inmultiplemetabolic derangements in diabetes (see Figure 2)
[9].
4.5. Activation of Diacylglycerol Protein Kinase C. Hyper-
glycemia stimulates formation of diacylglycerol, which then
activates PKC. The PKC is an important element in function
of nerves and pathogenesis of DN. Activation of PKC initiates
an intracellular signaling cascade such as overexpression of
PAI-1, NF-𝜅B, and TGF-𝛽. It also increases the production of
extracellular matrix and cytokines. Furthermore, it enhances
contractility, permeability, and vascular endothelial cell pro-
liferation such as motivation of cytosolic phospholipase A2
and inhibition of Na+/K+ ATPase (Figure 2) [9, 11]. PKC has
a unique structural feature that according to redox status of
cell facilitates its regulation. An antioxidant can react with
catalytic domain to inhibit its activity, while the prooxidants
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react with regulatory domain to stimulate its activity. On
activation, PKC triggers stress genes that phosphorylate tran-
scription factors and thus alter the balance of gene expression
resulting in oxidative stress [8].
4.6. Role of Oxidative Stress, Apoptosis, and Poly ADP-Ribose
Polymerase. The generation of free radicals is a major factor
in development of DN through increased glycolytic process.
Oxidative stress and reactive oxygen species (ROS) link the
physiological mediators and metabolic initiators implicated
in progressive nerve fiber damage, dysfunction, and loss in
DN. Simultaneous with generation of free radicals during
the glycolytic process, oxidative stress harms mitochondrial
DNA, proteins, and membranes [9, 12]. In fact, mitochon-
drial damage takes place due to surplus formation of ROS
or reactive nitrogen species (RNS). Hyperglycemia induces
mitochondrial changes such as release of cytochrome C,
activation of caspase 3, altered biogenesis and fission, which
all lead to a programmed cell death. Reduced mitochondrial
action potentials (MMP) with modest ATP are resulted
from thrilling entrance of glucose. This process results in
surplus transport of oxidant electrons into the mitochondria.
Neurotrophic support such as neurotrophin-3 (NT-3) and
nerve growth factor (NGF) are also reduced bymitochondrial
injury. It should be noted that axons are disposed to hyper-
glycemic hurt owing to their large content of mitochondria
[12]. Oxidative stress in conjunction with hyperglycemia
activates poly ADP-ribose polymerase (PARP) which further
cleaves nicotinamide adenine dinucleotide (NAD+) to nicoti-
namide and ADP-ribose residues. This process continues by
a link to nuclear proteins and results in changes of gene
transcription and expression, NAD+ depletion, oxidative
stress, and diversion of glycolytic intermediates to other
pathogenic pathways such as PKC and AGEs (Figure 2) [9].
Collectively, the polyol, AGEs, PKC, hexosamine, and PARP,
all contribute to neuronal damage together. The AGEs and
polyol pathways openly modify the redox capacity of the
cell either through weakening of necessary components of
glutathione recycling or by direct construction of ROS. The
hexosamine, PKC, and PARP pathways are representatives
of damage mediated through expression of inflammatory
proteins [9].
4.7. Nitric Oxide Deficiency/Impaired Endothelial Function.
Vascular factors include impaired nerve perfusion, hypoxia,
and nerve energetic defects that are all implicated in the
pathogenesis of DN. Nerve blood flow is reduced in DN
perhaps mediated via nitric oxide (NO). Overproduction of
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superoxide anion by the mitochondrial electron transport
chain in DN leads to binding of this anion to NO to form
the strong oxidant peroxynitrite which is right lethal to
endothelial cells. Endothelial cells also produce NO that
acts as a vasodilator and antagonizes thrombosis. The NO
also defends against inflammation by adjusting (Na+/K+)-
ATPase or inhibiting the production of potent vasoconstric-
tor peptide endothelin (ET)-1 [13, 14]. In addition, hyperho-
mocysteinemia is associated with impairment of endothelial
function, providing amechanism for its possible involvement
in DN. There is a synergistic effect between AGEs and
homocysteine in initiation of endothelial damage (Figure 2)
[13].
4.8. Inflammation. The nerve tissues in diabetes undergo
a proinflammatory process that presents symptoms and
develops neuropathy. In addition, inflammatory agents such
as C-reactive protein and tumor necrosis factor-𝛼 (TNF-
𝛼) are present in the blood of both type 1 diabetes (T1D)
and type 2 diabetes (T2D) patients. The levels of C-
reactive protein and TNF-𝛼 correlate with the incidence
of neuropathy. Production of the initiating inflammatory
mediators such as TNF-𝛼, TGF-𝛽, and NF-𝜅B results from
several glucose-induced pathways. Cyclooxygenase-2 (COX-
2) is an important enzyme that is upregulated by NF-𝜅B
in diabetic peripheral nerves and consecutively generates
prostaglandin E2 and ROS that trigger NF-𝜅B. Inducible
nitric oxide synthase (iNOS) is an additional inflammatory
enzyme which is regulated by NF-𝜅B. Similar to COX-
2, iNOS either induces NF-𝜅B or is induced by it. This
gives the impression that chronic NF-𝜅B activation is in the
center of all the inflammatory elements operating in DN.
Subsequent to ischemia reperfusion, an extensive andmodest
infiltration of macrophages and granulocytes takes place in
diabetic peripheral nerves. The cytokines which are induced
by NF-𝜅B in Schwann cells, endothelial cells, and neurons
lead to absorption of macrophages in the diabetic nerves.
Macrophages promote DN via a variety of mechanisms,
includingmaking of cytokines, ROS, and proteases, which all
result in cellular oxidative damage and myelin breakdown.
Excessive macrophage recruitment impairs regeneration of
nerves in DN [9, 12].
4.9. Growth Factors. Neurotrophic factors play roles in the
development, maintenance, and survival of neuronal tissue.
In DN, the Schwann cells are damaged and neurons disinte-
grate, and the growth factors such as NGF, NT-3 and insulin-
like growth factors (IGFs) are affected [9, 11].
5. Differences in the Pathophysiology of
T1D and T2D in DN
As noted, hyperglycemia is a fundamental factor in DN.
Dyslipidemia and changes in insulin signaling come after
hyperglycemia in T2D. Levels of both insulin and C-peptide
are reduced in patients with T1D while the neuronal insulin
sensitivity is reduced in T2D. Therefore, the circumstances
of disease in T1D and T2D are different, and this affects the
efficacy of some medications [3].
5.1. Dyslipidemia. Dyslipidemia with high incidence in T2D
is linked to DN. Free fatty acids have systemic effects such
as release of inflammatory cytokine from adipocytes and
macrophages. Plasma lipoproteins, especially low-density
lipoproteins (LDLs), can be modified by glycation or oxi-
dation where then binds to extracellular receptors compris-
ing the oxidized LDL receptor 1(LOX1), toll-like receptor
4(TLR4), and RAGEs that activate NADPH oxidase. All
these result in oxidative stress. Additionally, cholesterol can
be simultaneously oxidized to oxysterols to cause neuronal
apoptosis (Figure 2) [3].
5.2. Impaired Insulin Signaling. Insulin has neurotrophic
effects and promotes neuronal growth and the survival while
it is not involved in uptake of glucose into the neurons.
Reduction of this neurotrophic signaling due to insulin
resistance (T2D) or insulin deficiency (T1D) contributes
to the pathogenesis of DN. In neurons, insulin resistance
occurs by inhibition of the PI3K/Akt signalling pathway.
Disruption of this pathway leads to mitochondrial dysfunc-
tion, oxidative stress, and dysfunction or death of the nerve.
Tight glucose control is not as efficacious in patients with
T2D, whereas it can reduce neuropathy in patients with
T1D. This divergence is most likely related to differences
in the underlying mechanisms in terms of hyperglycemia,
dyslipidemia, and insulin resistance in T1D and T2D
[3].
6. Treatment of DN
6.1. Control of Hyperglycemia. As discussed above, hyper-
glycemia and/or insulin deficit and their concomitant actions
are principally involved in the pathogenesis of DN. Thus,
glycemic control gives the impression to be the most effective
treatment to delay onset of DN and slowing its progress
[14]. By contrast with the results obtained from patients
with T1D, glucose control produces less definitive effect in
patients with T2D.Therefore, despite the similarities between
T1D and T2D, there are dissimilarities in the mechanisms
and complications. It seems that glucose control is the only
disease-modifying therapy for DN, as uncontrolled diabetes
results in a pronounced oxidative stress that can be reversed
if patients attain glycemic control. According to assumption
that oxidative stress may mediate vascular, microvascular,
and specific tissue complications in diabetes, antioxidant
therapy remains a vital therapy [3]. Pain management is the
other buttress of treatment for DN that can largely improve
the quality of patients’ life. As shown in Table 1, over the
past two decades, enormous efforts have been made by
doing randomized placebo-controlled trials to find effective
treatments for DN. Based on these studies, several classes of
drugs are considered to be effective for the treatment of DN,
and also given the pathogenesis of DN, other drugs have been
suggested as disease modifying all based on oxidative stress
(Figure 3).
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Figure 3: Algorithm for treatment of DN pain. TCAs: tricyclic antidepressants; SSRIs: selective serotonin reuptake inhibitors; SNRIs:
serotonin norepinephrine reuptake inhibitors; NSAIDs: nonsteroidal anti-inflammatory drugs; ALC: acetyl-l-carnitine; ALA: 𝛼-lipoic acid;
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PARPIs: poly ADP-ribose polymerase inhibitors; ACEIs: angiotensin converting enzyme inhibitors; HXIs: hexosamine pathway inhibitors.
6.2. Current Pharmacotherapy of DN Independent of
Oxidative Stress
6.2.1. Tricyclic Antidepressants (TCAs). TheTCAs are recom-
mended as the first-line therapy to relief pain of DPN for
many years, even though they are not specifically endorsed
for it. TCAs besides affecting catecholamines, they inhibit
sodium and calcium channels, adenosine and N-methyl-D-
aspartate (NMDA) receptors on the way to suppress neuronal
hyperexcitability. TCAs have many side effects, principally
anticholinergic effects [98, 99]. A meta-analysis based on
number needed to treat (NNT) for TCAs resulted in the
scores of 2 to 3 with a number needed to harm (NNH) of 14.7
[100].
6.2.2. Selective Serotonin Reuptake Inhibitors (SSRIs) and Sero-
tonin Norepinephrine Reuptake Inhibitors (SNRIs). Because
of the relative high rate of adverse effects and several
contraindications of TCAs, the SSRIs can be considered
for those who do not tolerate TCAs. The SSRIs inhibit
presynaptic reuptake of serotonin but not norepinephrine,
and unlike TCAs, they lack postsynaptic receptor blocking
effects and quinidine-like membrane stabilization. There is
limited evidence showing a beneficial role for SSRIs, as they
have not been licensed for the treatment of DN pain [14,
99, 101]. Antidepressants with dual selective inhibition of
serotonin and norepinephrine (SNRIs) such as duloxetine
and venlafaxine are better. SNRIs block the noradrenaline and
5-HT transporters and inhibit monoamine reuptake from
the synaptic cleft into the presynaptic terminal which finally
result in inhibition of excitatory impulse and pain perception
[98, 101–103].
6.2.3. Anticonvulsants. Gabapentin and pregabalin should
be used as first-line treatment for DPN pain if there is
inadequate response or contraindications to TCAs. Prega-
balin and gabapentin bind to the alpha2-delta subunit of the
calcium-sensitive channels on the presynaptic neuron and
modulate neurotransmitter release [99, 100]. Based on the
new guidelines, pregabalin is recommended for the treatment
of painful DN [102, 103]. Sodium valproate is probably
effective in lessening pain and should be considered for the
treatment of painful DN, but its adverse effects are high.
For instance, it can worsen glycemic control and weight
gain. Lamotrigine, oxcarbazepine and lacosamide should
probably not be considered for the treatment of painful DN.
Topiramate also lacks adequate support to be used in DN
[103].
6.2.4. Opioids. Opioids by interacting with receptors located
on neuronal cell membranes prevent neurotransmitter
release at the presynaptic nerve terminal and reduce pain [14].
Controlled-release oxycodone, tramadol, and morphine can
be exampled [99]. A meta-analysis indicated an NNT of 2.6
for oxycodone, 3.9 for tramadol, and 2.5 for morphine [100]
in the treatment of painful DN [103].
6.2.5. Topical Medications. Current topical treatments for
DPN pain include capsaicin cream and lidocaine 5% patches.
This combination stimulates C fibers to release, and sub-
sequently deplete substance P. Capsaicin application causes
degeneration of epidermal nerve fibers as a mechanism of
its analgesic effect, and thus caution for its use in insensitive
diabetic foot is needed [14]. In a 2009 pooled data analysis,
the calculated NNT for capsaicin was 5.7 [53]. Lidocaine
blocks voltage-gated channels in damaged nerves [99]. There
have been small effective trials with lidocaine. A randomized
controlled trial (RCT) in 2003 revealed an NNT of 4.4 for it
[67]. Topical clonidine is probably not effective and should
not be considered [103].
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6.2.6. Antipsychotics. Few atypical antipsychotics have been
introduced for painful DN. The newer, less dopamine selec-
tive antipsychotics was supported by some animal studies
consistent with clinical trials [104]. These compounds may
induce negative metabolic effects such as weight gain and
insulin resistance [105].
6.2.7. Anesthetics/Antiarrhythmic. These agents are all potent
voltage-gated sodium channel antagonists and perhaps are
less used in DN [105]. Mexiletine, lidocaine, and tocainide
have all shown benefits for painful DN in smaller RCTs.
Although tocainide has positive effects, but caution is needed
for its cardiotoxicity [105]. Mexiletine has not been found
effective [103]. The easiest method to incorporate the utility
of the anesthetic/antiarrhythmics in patients with painful DN
is the use of 5% lidocaine patches [105].
6.2.8. Vasodilators. Isosorbide dinitrate nasal spray and glyc-
eryl trinitrate transdermal patches have shown positive
effects in painful DN [105].
6.2.9. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). In
patients with acute painful peripheral neuropathy, simple
analgesics such asNSAIDsmay provide pain control bymod-
ulating the nociceptive and inflammatory pain pathways [14].
6.2.10. NMDA Antagonists. Dextromethorphan, a low affin-
ity NMDA receptor blocker, has been effective in relieving
pain and improving quality of life in patients with DN [103].
6.2.11. Botulinum Toxin. This toxin not only works on the
acetylcholine channels but also involves other mechanisms.
Existing studies lack large number of subjects, and more is
required to overcome doubt and debate about efficacy of this
toxin [105].
6.3. Treatments Dependent on Oxidative Stress. The strongest
sign for the role of oxidative stress in DN is the studies that
report positive effects of antioxidants in both animal models
and patients. Although, it is impossible to review all the
antioxidants that can be effective to prevent or delay the onset
of DN, some can be listed such as acetyl-L-carnitine, taurine,
𝛽-carotene, free amino acids, vitamin E, curcumin, ascorbic
acid, and lipoic acid [8].
6.3.1. Taurine. Taurine is an antioxidant with effects on neu-
ronal calcium signaling. Taurine improves electrophysiolog-
ical parameters and nerve blood flow and exhibits analgesic
properties in patients with DN [14].
6.3.2. Acetyl-L-Carnitine. Acetyl-L-carnitine (ALC), the ace-
tylated ester of the amino acid L-carnitine, as an antioxidant
has shown significant reduction in pain of patients with DN
[14].
6.3.3. Alpha Lipoic Acid. D-L-𝛼-lipoic acid (ALA) is a potent
antioxidant, which has been extensively evaluated in subjects
with DN and has shown good effects [14]. But based on new
guidelines, there is insufficient evidence to recommend it in
treatment of DN [103].
6.4. Nonpharmacologic Agents. Percutaneous electrical nerve
stimulation is probably effective in reducing pain and
improving sleep in patients who have painful DN. Exercise
and acupuncture lack evidence of efficacy in the treatment
of painful DN. Low-intensity laser therapy, Reiki therapy,
and electromagnetic field treatment (such as magnetized
shoe insoles) are probably not effective and should not be
considered [103].
6.5. Therapies on the Horizon Based on Oxidative Stress.
Since constant tight glucose control is difficult and still
a challenge in most cases, additional therapies that target
the hyperglycemia-induced complications are now under
attention of researchers. To this end, coping against some
known pathways that are activated as a consequence of
increased oxidative stress and glucose flux is deemed effective
to control DN. These pathways and inhibition of them are
reviewed below.
6.5.1. Protein Kinase C Inhibitors. It is thought that activa-
tion of PKC through hyperglycemia-induced oxidative stress
contributes to the generation of free radicals that result in
diabetic microvascular complications [14]. Some of the PKC
inhibitors such as ruboxistaurin have been shown to exhibit
antioxidant effects. Ruboxistaurin has been particularly suc-
cessful in reducing the progress of DN, and it is pending to
get official approval [106].
6.5.2. Aldose Reductase Inhibitors (ARIs). As stated earlier,
hyperglycemia-mediated activation of the polyol pathway
can produce oxidative stress that may underlie DN. Aldose
reductase is a key enzyme in pathogenesis of DN. ARIs drop
the flux of glucose through the polyol or sorbitol pathways
resulting in a reduction of intracellular accumulation of
sorbitol and fructose [14]. The effects of fidarestat (a novel
ARIs) on nerve conduction and the subjective symptoms of
DN provided evidence that this treatment can control DN
with concomitant reduction in oxidative stress markers [107].
Similarly long-term treatment with epalrestat, an ARI, can
effectively delay the progress of DN and improve the symp-
toms, particularly in subjects with limited microangiopathy
and good glycemic control [108]. Treatment with ranirestat
(ARIs) also appears to have an effect onmotor nerve function
in mild to moderate diabetic sensorimotor polyneuropathy
(DSP), but the results of this study did not show a statistically
significant difference in sensory nerve function relative to
placebo [109].
6.5.3. Advanced Glycation End Product Inhibitors (AGEIs).
Accumulation of AGEs and activation of AGE receptors
lead to oxidative stress and microvascular damage in DN.
Benfotiamine, a derivative of thiamine (vitamin B1), reduces
tissue AGEs formation and oxidative stress in subjects
with DN with varying doses and duration of treatment
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[14, 110]. Also aspirin, because of its antioxidant capacity,
and aminoguanidine, a free radical scavenger, can inhibit this
pathway and reduce oxidative stress in DN [9].
6.5.4. Hexosamine Pathway Inhibitors. As described above,
diabetes-induced oxidative stress stimulates hexosamine
pathway that implicates in the pathology of DN. Benfoti-
amine decreases flux through hexosamine pathway resulting
in lower oxidative stress. This agent can reduce the pain
associated with DN [9].
6.5.5. Inhibition of PARP. As discussed above, PARP acti-
vation involves in the pathogenesis of DN, and its inhibi-
tion lightens numerous experimental pathologic conditions
connected with oxidative stress in DN. Nicotinamide has
been shown to act as a PARP inhibitor and an antioxidant in
animals that improves complications of early DN [9].
6.5.6. Angiotensin Converting Enzyme Inhibitors. Angiot-
ensin II is a potent vasoconstrictor with proinflamma-
tory properties, which especially in the absence of NO
causes thrombosis. It also stimulates intercellular adhesion
molecules and vascular adhesion molecules (VCAMs). The
role of angiotensin converting enzyme inhibitors in DN is
probably through inhibition of angiotensin II. In this regard,
trandolapril has shown a small but significant improvement
in some complication of DN [14].
7. New Therapeutic Approaches for DN
Despite relative lack of success of interventional agents to
reverse or slow establishedDN, there is still hope to find some
good agents.We have summarized a few of new approaches in
Table 2 [79–97]. Hopefully, some reviews in the recent years
have proven positive effects of natural antioxidants andherbal
products such as Satureja species andUrtica dioica in diabetes
and its complications [111–116].
8. Conclusion
In the present review,we tried to elaborate the pathogenesis of
disease with a focus on oxidative stress and introduced ther-
apies dependent or independent of oxidative stress. Diabetes
can injure peripheral nerves in various distributions, and
DSPN is the most common presentation in diabetes, which
lead to substantial pain, morbidity, and impaired quality of
life. Social and health-care costs linked with DN are high. DN
develops on a background of hyperglycemia and associated
metabolic imbalance. Numerous biochemical mechanisms of
neurovascular and nerve damage have been identified in DN,
but excessive production of ROS or oxidative stress is thought
to be a common etiologic factor.
Treatment of DN always begins with optimizing glycemic
control and then control of pain. Regarding role of oxidative
stress and consequential factors in pathogenesis of DN,
observing positive results with inhibitors of key pathways
at the preclinical level is not surprising, but final decision
will be made on the basis of clinical trials. If oxidative stress
is assumed only as an ancillary player in DN, then antioxi-
dants should be supplemented with conventional treatments.
Development of new drugs to treat DN still remains a
challenge that needs intensive long-term comparative trials.
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